Combination therapy shows no added survival benefit in patients with cervical cancer
MD Anderson Research Highlight March 24, 2025
Patients with intermediate-risk cervical cancer often receive chemotherapy with radiation therapy after surgery, but the added benefit of this combination remains unclear. To address this, researchers including N¨²ria Agust¨ª, M.D., and , analyzed data from 1,116 patients with cervical cancer, examining overall survival rates among those receiving chemoradiotherapy compared to radiotherapy alone. There was no significant difference between the groups, with both achieving an 87% five-year survival rate. These findings suggest that adding chemotherapy to radiation after surgery may not improve survival in these patients, highlighting a need to de-escalate adjuvant treatment. Future studies should focus on defining more precise criteria to identify which patients truly benefit from adjuvant treatment, potentially through targeted therapies that minimize unnecessary toxicity. Learn more in .
Despite the widespread use of adjuvant chemoradiotherapy in this setting, our study shows no survival advantage over radiotherapy alone. These results support a more selective approach, reducing unnecessary toxicity for patients with intermediate-risk cervical cancer